Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06378658
Status:
COMPLETED
Last Update Posted:
2024-07-05
First Post:
2024-03-19
Brief Title:
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Phase 1 Open Label Randomized Crossover Study to Investigate the Effect of Food and Effect of an Acid Reducing Agent on the Pharmacokinetics of BAY 2927088 in Healthy Participants
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer NSCLC with specific genetic changes called epidermal growth factor receptor EGFR and human epidermal growth factor receptor 2 HER2 mutations
Advanced NSCLC refers to a type of lung cancer that has spread from the lungs to nearby tissues or other body parts People with advanced NSCLC may have changes in certain proteins like EGFR and HER2 that cause uncontrolled cell growth and increased spread of cancer
In this study participants will be healthy and will not benefit from taking the study treatment BAY2927088 However the study will provide information about how to test BAY2927088 in future studies with people who have advanced NSCLC with EGFR or HER2 mutations
BAY2927088 is under development for the treatment of advanced NSCLC with EGFR or HER2 mutations It is expected to work against these changed proteins which might slow down the spread of cancer
The absorption of BAY2927088 into the blood is dependent on the amount of acid present in the stomach Esomeprazole is a medicine which is used in the treatment of heartburn and excessive acid in the stomach Both food and esomeprazole may change the amount of acid present in the stomach
The main purpose of this study is to find out how food and esomeprazole may affect the absorption of BAY2927088 into the blood of healthy participants For this researchers will measure the levels of BAY2927088 in participants blood when it is given with or without food as well as with or without esomeprazole Researchers will then calculate the following
Area under the curve AUC a measure of the total amount of BAY2927088 in participants blood over time
Maximum observed concentration Cmax the highest amount of BAY2927088 in participants blood
The study will have 4 treatment periods
- Periods 1 to 3 Day 1 to Day 9 All participants will take BAY2927088 with a low-fat meal with a high-fat meal and on an empty stomach but in a different order over the 3 study periods Each period will last for 3 days and BAY2927088 will be given on the first day of each period
On Day 9 participants will take esomeprazole on an empty stomach
- Period 4 Day 10 to Day 14 On Days 10 and 11 participants will take esomeprazole on an empty stomach On Day 12 participants will take esomeprazole on an empty stomach After 1 and a half hours participants will take low-fat meal and BAY2927088
On Day 13 participants will take esomeprazole on an empty stomach
Participants will be in this study for about 8 weeks with 3 visits to the study clinic
Participants will visit the study clinic
at least once 2 to 28 days before the treatment starts to confirm they can take part in this study
once on the day before the treatment starts and will stay in the clinic until Day 14 of the treatment
once 7 to 10 days after last dose of BAY2927088 for a health check-up
During the study the doctors and their study team will
do physical examinations
collect blood samples from the participants to measure the levels of BAY2927088
check participants health by performing tests such as blood and urine tests and checking heart health using an electrocardiogram ECG
ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study The study doctors keep track of all adverse events irrespective of whether they think it is related or not to the study treatment
Advanced NSCLC refers to a type of lung cancer that has spread from the lungs to nearby tissues or other body parts People with advanced NSCLC may have changes in certain proteins like EGFR and HER2 that cause uncontrolled cell growth and increased spread of cancer
In this study participants will be healthy and will not benefit from taking the study treatment BAY2927088 However the study will provide information about how to test BAY2927088 in future studies with people who have advanced NSCLC with EGFR or HER2 mutations
BAY2927088 is under development for the treatment of advanced NSCLC with EGFR or HER2 mutations It is expected to work against these changed proteins which might slow down the spread of cancer
The absorption of BAY2927088 into the blood is dependent on the amount of acid present in the stomach Esomeprazole is a medicine which is used in the treatment of heartburn and excessive acid in the stomach Both food and esomeprazole may change the amount of acid present in the stomach
The main purpose of this study is to find out how food and esomeprazole may affect the absorption of BAY2927088 into the blood of healthy participants For this researchers will measure the levels of BAY2927088 in participants blood when it is given with or without food as well as with or without esomeprazole Researchers will then calculate the following
Area under the curve AUC a measure of the total amount of BAY2927088 in participants blood over time
Maximum observed concentration Cmax the highest amount of BAY2927088 in participants blood
The study will have 4 treatment periods
- Periods 1 to 3 Day 1 to Day 9 All participants will take BAY2927088 with a low-fat meal with a high-fat meal and on an empty stomach but in a different order over the 3 study periods Each period will last for 3 days and BAY2927088 will be given on the first day of each period
On Day 9 participants will take esomeprazole on an empty stomach
- Period 4 Day 10 to Day 14 On Days 10 and 11 participants will take esomeprazole on an empty stomach On Day 12 participants will take esomeprazole on an empty stomach After 1 and a half hours participants will take low-fat meal and BAY2927088
On Day 13 participants will take esomeprazole on an empty stomach
Participants will be in this study for about 8 weeks with 3 visits to the study clinic
Participants will visit the study clinic
at least once 2 to 28 days before the treatment starts to confirm they can take part in this study
once on the day before the treatment starts and will stay in the clinic until Day 14 of the treatment
once 7 to 10 days after last dose of BAY2927088 for a health check-up
During the study the doctors and their study team will
do physical examinations
collect blood samples from the participants to measure the levels of BAY2927088
check participants health by performing tests such as blood and urine tests and checking heart health using an electrocardiogram ECG
ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study The study doctors keep track of all adverse events irrespective of whether they think it is related or not to the study treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None